Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Beats on EPS, Stock Up 2.18%

Ligand Pharmaceuticals reported a significant earnings surprise with an EPS of $1.03, leading to a 2.18% increase in stock price. The strong EPS performance indicates better-than-expected profitability, although the lack of revenue data leaves some uncertainty. Investors may view this as a positive sign of operational efficiency, but the absence of guidance could lead to cautious sentiment in the near term.